Cencora, Inc. (NYSE:COR) Shares Acquired by NEOS Investment Management LLC

NEOS Investment Management LLC lifted its stake in shares of Cencora, Inc. (NYSE:COR) by 25.6% during the 4th quarter, Holdings Channel reports. The fund owned 6,074 shares of the company’s stock after buying an additional 1,238 shares during the quarter. NEOS Investment Management LLC’s holdings in Cencora were worth $1,365,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of COR. JFS Wealth Advisors LLC boosted its holdings in Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after purchasing an additional 46 shares during the last quarter. SBI Securities Co. Ltd. acquired a new stake in Cencora during the fourth quarter worth $30,000. Kentucky Trust Co purchased a new stake in Cencora in the fourth quarter valued at $33,000. Householder Group Estate & Retirement Specialist LLC lifted its stake in shares of Cencora by 85.2% in the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after purchasing an additional 69 shares during the last quarter. Finally, WASHINGTON TRUST Co grew its holdings in shares of Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock worth $38,000 after purchasing an additional 46 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Up 0.4 %

COR stock opened at $275.16 on Friday. The company’s 50 day moving average price is $253.81 and its 200 day moving average price is $241.21. The firm has a market capitalization of $53.36 billion, a price-to-earnings ratio of 39.14, a PEG ratio of 1.31 and a beta of 0.51. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $275.57. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were issued a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.80%. Cencora’s payout ratio is currently 31.29%.

Insider Transactions at Cencora

In other news, EVP Silvana Battaglia sold 5,000 shares of the company’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the transaction, the executive vice president now owns 15,374 shares in the company, valued at approximately $3,724,197.76. This represents a 24.54 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Lazarus Krikorian sold 2,000 shares of Cencora stock in a transaction on Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the sale, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. This represents a 9.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,675 shares of company stock valued at $8,034,778. Corporate insiders own 10.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on COR. Evercore ISI boosted their price target on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Mizuho assumed coverage on Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target on the stock. JPMorgan Chase & Co. raised their price target on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. StockNews.com upgraded Cencora from a “hold” rating to a “buy” rating in a report on Wednesday, March 12th. Finally, Wells Fargo & Company raised their target price on Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a report on Friday, March 14th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $280.20.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.